In addition, other drug- or toxicity -related candidate genes relevant for paclitaxel-carboplatin treatment in ovarian cancer (such as GSTA-1 [32], MAD1L1 [43], OPRM1 [44], TRPV1 [44], ...) could be selected based on pharmacogenetic knowledge bases such as pharmGKB (www.pharmgkb.org). Here, OPRM1 is linked to ovarian carcinoma.